Clinical trial
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)
ClinicalTrials.gov ID: NCT01568866
Sponsor: Amgen
Information provided by: Amgen (Responsible Party)
Last Update Posted: 2022-11-14
Brief Summary:
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Official Title:
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Intervention / Treatment:
- Drug: Carfilzomib
- Drug: Bortezomib
- Drug: Dexamethasone
| Category | Value |
|---|---|
| Study Start (Actual) | 2012-06-20 |
| Primary Completion (Actual) | 2014-11-10 |
| Study Completion (Actual) | 2018-02-05 |
| Enrollment (Actual) | 929 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
2011-003
2012-000128-16 (EudraCT Number) |